Granules India net profit up 80 percent at Rs 145 crore in Q2

Published On 2022-10-22 05:59 GMT   |   Update On 2022-10-22 05:59 GMT
Advertisement

Bengaluru: Pharmaceutical company Granules India Ltd reported an 80% surge in quarterly profit on Thursday, boosted by higher sales of the painkiller drug Paracetamol.

Consolidated profit for the company, which also makes the anti-inflammatory drug Ibuprofen, came in at 1.45 billion Indian rupees ($17.43 million) for the three months ended Sept. 30, compared with 806.8 million rupees in the year ago.
The company said 51% of its revenue came from finished dosages, which is its biggest business. Active pharmaceuticals ingredients and pharmaceutical formulation intermediates contributed 29% and 20%, respectively, to its revenue.
"Opportunities in Paracetamol are likely to continue and our geography expansion strategy in Europe is likely to yield bigger turnover and EBITDA in future periods," Granules Chairman Krishna Prasad Chigurupati said in a statement.
Consolidated revenue rose 29.5% to 11.51 billion rupees.

Read also: Granules India bags USFDA okay for Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets

Granules India is an Indian pharmaceutical manufacturing company that was founded in 1984 and named Triton Laboratories located in Hyderabad, India.

Granules manufactures varieties of drugs including Paracetamol, Ibuprofen, Metformin, and Guaifenesin, on a large scale for customers in the domestic as well as international markets.

Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News